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spondylitis (AS). METHODS: Inﬂiximab and etanercept signiﬁ-
cantly improve signs and symptoms of AS. We analyzed their
cost-efﬁcacy based on incremental beneﬁt versus placebo in their
respective AS pivotal trials. Inclusion and exclusion criteria were
similar for both trials except for permitted concomitant medica-
tions. The base model estimates cost efﬁcacy for maintenance
therapy, compared to placebo. Costs were estimated based on
average dose for a patient receiving maintenance therapy over a
1-year period. The average number of inﬂiximab vials per dose
(4) and total doses/year per patient (8) were obtained from
ASSERT trial data. Etanercept was assumed to be administered
at 25mg/dose twice weekly. The ASAS 20, ASAS partial remis-
sion, DCART 20 response rates, and percent improvement in
BASFI at week 24 were used as efﬁcacy measures. RESULTS: In
the inﬂiximab trial, 201 patients received inﬂiximab (5mg/kg)
and 78 patients received placebo. In the etanercept trial, 138
patients were treated with etanercept 25mg twice weekly and
139 received placebo. The cost per responder for inﬂiximab as
measured by ASAS 20, ASAS partial response, and DCART 20
was $44,790, $89,156, and $54,057, respectively. The corre-
sponding costs per responder for etanercept were $43,271,
$116,500, and $58,250. The mean percent improvement in
BASFI in the inﬂiximab and placebo arms were 38.5% and 0.1%
respectively, leading to a cost per percent BASFI improvement of
$490. The corresponding numbers for etanercept were 30% and
2%, leading to a cost per percent BASFI improvement of $541.
CONCLUSIONS: The cost-efﬁcacy ratios of inﬂiximab and
etanercept maintenance therapies compared to placebo were
similar. The cost-effectiveness in clinical practice will depend on
the actual dose and effectiveness achieved. Incremental cost-
effective comparisons cannot be reliably estimated without a
head-to-head trial.
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OBJECTIVES: To render information on the accuracy of patient-
reported indirect cost data. By comparing questionnaire-derived
data to payer-derived data on a patient-by-patient basis disease
related productivity losses in rheumatoid arthritis (RA) are being
validated. METHODS: The assessment of indirect cost data was
part of a clinical multicenter randomized RA-trial in Germany.
For 234 RA-patients at working age (1987 ACR criteria, mem-
bership in the regional statutory health insurance plan, mean age
53 (±9) years, mean disease duration 8 (±7) years, 76% females)
every three months corresponding indirect cost data were derived
from (i) a health economic questionnaire for cost assessment in
patients with RA and (ii) the payer’s database (insurance and
physicians’ association) over a period of 18 months. Compara-
tive statistical analyses were performed between patient reported
and insurance claims data. RESULTS: The mean annual pro-
ductivity losses due to sick leave amounted to 14 and 17 days
per patient (questionnaire versus payer data), productivity losses
due to work disability to 3 days (both); monetary valuation
renders overall costs of 1240€ and 1590€, respectively. The dif-
ference of 17% in overall productivity losses is not signiﬁcant.
Comparison of productivity losses reveals a strong correlation of
r = 0.83 in those due to sick leave and of kappa = 0.84 in those
due to work disability between questionnaire and payer data.
CONCLUSIONS: The comparison of questionnaire and payer
data shows that RA-patients report their productivity losses ade-
quately. Indirect cost assessment should therefore be included in
further RA-trials and observational studies, even if payer-derived
data is not available.
PAR13
COST-EFFECTIVENESS OF VALDECOXIB COMPARED TO
DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS
(RA) IN THE UK (UK) AND GERMANY
Alten RH1, von Scheele B2, Gaffney L3, Maciver F3, Niculescu L4
1Schlossparkklinik, Berlin, Germany; 2RTI Health Solutions, Södra
Sandby, Sweden; 3RTI Health Solutions, Manchester, UK; 4Pﬁzer Inc,
New York, NY, USA
OBJECTIVE: To compare the cost-effectiveness of valdecoxib 20
mg once daily (qd) and diclofenac 75mg slow release (SR) twice
daily (bid) in the treatment of RA based on prospectively col-
lected data of Health Care resource utilization in a randomized
controlled trial (RCT, study 062) over 6 months. The cost-
effectiveness evaluations were calculated for the UK from a
National Health Service payer perspective, and for Germany
from a Sickness funds payer perspective. METHODS: Study 062
compared efﬁcacy and safety of valdecoxib 20mgqd (n = 246)
with diclofenac 75mg SR bid (n = 237) in adult patients with
RA. The cost-effectiveness of valdecoxib and diclofenac was
compared using country-speciﬁc unit costs for resource use (hos-
pital days, medications, unscheduled procedures and health care
visits) in the UK and Germany. The cost-effectiveness ratios were
calculated for cost/averted gastroduodenal (GD) ulcer,
cost/averted withdrawal due to treatment failure and/or adverse
event, cost/averted gastrointestinal (GI) serious adverse event
(SAE), and cost/avoided ulcer with GI SAE. RESULTS: The study
showed comparable efﬁcacy and a superior safety proﬁle for
valdecoxib, resulting in fewer GI adverse events and hospital
days. The cost/averted GD ulcer in the UK was -£1104 and 386€
in Germany. The cost/averted withdrawal due to treatment
failure and/or adverse event was -£1580 in the UK and 553€ in
Germany. The cost/averted GI SAE was -£2709 in the UK and
947€ in Germany, and the cost/avoided ulcer with GI SAE was
-£3522 in the UK and 1436€ in Germany. CONCLUSIONS: The
superior safety proﬁle of valdecoxib compared with diclofenac
translates into lower total health care costs for patients treated
with valdecoxib, and overall cost effectiveness in both countries.
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OBJECTIVES: To develop a systematic set of German cost data
in RA based solely on valid health care payer’s cost data sources
on a patient—per—patient micro-costing level. METHODS:
Retrospectively one-year cost data of 338 RA patients were gen-
erated and analyzed. The cost data were derived from a major
statutory health insurance plan (“Allgemeine Ortskrankenkasse
Niedersachsen”) and the regional physicians’ association
(“Kassenärztliche Vereinigung Niedersachsen”). A matrix of cost
domains in RA was applied to structure the analysis. Descriptive
statistics were used to analyze the data. RESULTS: The total
direct costs for the 338 patients during the one year period (3rd
quarter 2000—2nd quarter 2001) were 3815€ per patient-year.
RA-related direct costs were 2312€ per patient-year. Outpatient
costs accounted for 73.7%, inpatient costs for 24.0%, and other
disease-related costs for 2.3% of RA-related direct costs. Out-
patients costs drivers were: RA-related medication (1019€ per
patient-year), physician visits (323€ per patient-year), diagnostic
and therapeutic procedures and tests (185€ per patient-year), and
devices and aids (168€ per patient-year). Ninety-eight patients
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were retired prematurely due to RA-related work disability and
incurred costs of 8358€ per retired patient-year. Ninety-six
patients were gainfully employed and incurred sick leave costs
of 2835€ per employed patient-year. CONCLUSIONS: Micro-
costing based on health care payer’s data provides a relatively
conservative albeit highly accurate estimate of costs in RA. It is
important to take both RA-related and non-RA-related costs into
account. Medication costs are the dominant direct component
with an increase due to the introduction of biologic agents. In
gainfully employed patients and in patients who receive RA-
related retirement payments productivity costs exceed direct
costs.
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OBJECTIVE: Rheumatoid Arthritis (RA) is a disease with high
socioeconomic impact. Anti-TNF drugs have provided evidence
of effectiveness in treating RA patients resistant to 2 previous
conventional DMARDs, including MTX, as demonstrated by a
number-needed-to-treat (NNT) of 2 to produce a 20% improve-
ment in American College of Rheumatology (ACR) score
(ACR20). Anti-TNF therapy is also costly. The aim of this 
retrospective longitudinal cost of care analysis was to evaluate
the cost of Etanercept (ETA) vs Inﬂiximab (IFX) used at the 
standard dosage (according to the ANTARES Protocol) for the
treatment of RA patients after DMARDs (disease-modifying
anti-rheumatic drugs) failure in Italy. METHODS: The study
included subjects randomly enrolled from 7 centres participating
to a prospective data collection program called ANTARES.
Direct health care resources attributable to RA management
(drugs, ambulatory care, day case treatments, hospitalizations)
were quantiﬁed using National Health Service (NHS) tariffs
expressed in Euro 2003. NHS perspective was adopted. Multi-
ple linear regression techniques were used to investigate differ-
ences between IFX and ETA in the direct cost, adjusting for sex,
age, baseline ESR (erythrocyte sedimentation rate), baseline DAS
(disease activity score) and centre. RESULTS: A total of 211 (IFX
101, ETA 110) patients affected by RA (F/M 165/46; mean age
50.7 ± 14.5 years old) were studied. Mean total annual direct
costs for RA patients were euro 16,988 (±7245). The regression
analysis showed that adjusting for sex, baseline ESR, age, base-
line DAS and centres total direct costs per patient in ETA group
were 3427 Euro lower than in IFX patients (P < 0.0001). CON-
CLUSIONS: The total direct cost of Etanercept is statistically sig-
niﬁcantly lower than Inﬂiximab, when the drug are used at the
standard dosage, according to the ANTARES Protocol.
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OBJECTIVES: The aim was to focus on the ﬁnancial burden of
co-payments for patients with rheumatoid arthritis under new
German law regulations. METHODS: The assessment of all cost
data was part of a clinical multicenter randomized RA-trial in
Germany. For 136 RA-patients (1987 ACR criteria, mean age
57.4 (±12.5) years, mean disease duration 8.2 (±8.4) years, 77%
females) every 3 months corresponding cost data were derived
from 1) a RA-related patient-centered health economic ques-
tionnaire, and 2) the payer’s database (insurance and physicians’
association) over a period of 18 months. Co-payments in
Germany partly can be derived by analyzing the payers’ data due
to speciﬁc legal regulations. In addition to that patient-derived
data was evaluated. RESULTS: The data was composed in a
matrix of different cost domains. Those led to patient co-
payments/ year of 417.10€. Visits to a physician accounted for
9.2% (38.40€), non-physician service utilization for 46.6%
(194.40€), medication for 23.7% (99€), hospital co-payments
for 5.8% (24€), transportation for 13.5% (56.20€), and devices
and aids for 1.2% (5.10€) of the overall co-payment costs. CON-
CLUSIONS: The impact of co-payments on patients with
chronic diseases needs to be addressed by policy makers. Even
in an environment with relatively low co-payment regulations
like Germany the burden for RA-patients can become substan-
tial.
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OBJETIVES: ARTS is a self reported instrument designed to
measure four treatment satisfaction dimensions: Treatment
advantages, Treatment convenience, Apprehension about treat-
ment and Satisfaction with medical care; and is composed by 18
Likert-scale items. It is intended to be used with patients suffer-
ing osteoarthritis and undergoing oral administered treatments.
METHODS: Linguistic adaptation was performed using the
standard processes for establishing conceptual equivalence. A
panel of six experts supervised the process and four independent
translators translated and back-translated the items. A sample of
163 patients was used to gauge psychometric properties. All
patients suffered from knee, hip or column arthritis. Patients
were included in 3 groups: treatment-switch because of a weak
analgesic effect, treatment-switch due to poor tolerability and
no-change. The ARTS was administered at baseline, 1 week later
and after 4 weeks of therapy with traditional NSAIDs or Cox II-
inhibitors. RESULTS: Mean age was 67.7 ± 9.2 years old. The
adapted instrument showed good feasibility and reliability prop-
erties. No ﬂoor or ceiling effects where found, items where well
understood and non-response rates were below one percent
(1%). Cronbach’s alpha for the total scales was 0.85. Instrument
was stable with a test-retest intraclass correlation coefﬁcient of
0.83. Exploratory factor analysis yielded four dimensions coher-
ent with those proposed by the original authors. Convergent
validity was measured against SF-36, a pain VAS a treatment
compliance VAS, and Morisky-Green compliance questionnaire.
The adapted instrument showed good discriminant validity,
being able to distinguish between patients needing a change in
